Differential expression of a novel serine protease homologue in squamous cell carcinoma of the head and neck

JC Lang and DE Schuller
The Ohio State University, Department of Otolaryngology and Comprehensive Cancer Center, 1248 James Cancer Hospital and Solove Research Institute, 300 West 10th Avenue, Columbus, Ohio 43210, USA

Summary Differential gene expression between squamous cell carcinoma of the head and neck and matched normal tissue was studied by utilizing Representational Difference Analysis. Using this methodology, a novel gene, DESC1 was isolated. DESC1 possesses strong identity to the serine protease super-family. Comparison of DESC1 expression between primary squamous cell carcinoma and matched normal tissue shows that the level of DESC1 expression is reduced or absent in 11/12 SCC tissue specimens when compared to specimens of matched normal tissue. Tissue-specific expression studies further show that DESC1 expression can only be detected in tissues derived from the head and neck, and in skin, prostate and testes. Cell line studies demonstrate that DESC1 expression is epithelial-specific. Chromosomal localization studies indicate that DESC1 is located on the long arm of chromosome 4 at position q12–13. © 2001 Cancer Research Campaign http://www.bjcancer.com

Keywords: serine protease; DESC1; squamous cell carcinoma; head and neck; differential expression; chromosomal location

Investigation of the genetic alterations underlying squamous cell carcinoma of the head and neck (SCCHN) has recently allowed identification of a number of key genes frequently altered during disease progression. Many of these studies have concentrated on the role of oncogenes and tumour suppressor genes in the disease. Thus, oncogenes c-myc (Field et al, 1989), EGFR (Ke et al, 1998), HER-2/neu (Xia et al, 1997) and cyclin D1 (Michalides et al, 1995), and tumour suppressor genes p53 (Somers et al, 1992) and p16 (Reed et al, 1996; Lang et al, 1998), demonstrate disease-specific alterations during genesis of SCCHN. However, a number of studies have implicated additional chromosomal loci in the disease, suggesting the existence of additional unidentified genes, which may be targets for inactivation during SCCHN development (Nawroz et al, 1994; Califano et al, 1996; Loughran et al, 1997; Bockmuhl et al, 1998).

In this study, we have performed Representational Difference Analysis (RDA) (Diatchenko et al, 1996) in order to identify novel genes expressed in normal epithelium but absent from SCC. This study has allowed isolation of a differentially expressed novel gene named DESC1. DESC1 possesses strong identity to members of the serine protease superfamily, and shows highest degree of homology with Human Airway Trypsin-like protease (HAT; Yamaoka et al, 1998).

MATERIALS AND METHODS

RNA isolation

Normal human keratinocytes (NHEK-Neo, NHEK-Ad) and prostate epithelial cells (PrEC) were cultured in keratinocyte growth medium (KGM) or prostate epithelial cell growth medium (PrEGM) (Clonetics, San Diego, CA) respectively and exponentially growing cells harvested. Tissue samples were provided by the Cooperative Human Tissue Network, funded by the National Cancer Institute. Total RNA was extracted from cell lines and tissue as previously described (Gramza et al, 1995). Normal prostate and testes RNA was obtained from CLONTECH (Palo Alto, CA) and normal skin RNA from Invitrogen (Carlsbad, CA). Polyadenylated RNA was selected utilizing an Oligotex kit (Qiagen, Santa Clarita, CA).

Representational difference analysis and gene cloning

Representational Difference Analysis (RDA) was performed by utilizing PCR-Select cDNA subtraction methodologies (CLONTECH, Palo Alto, CA) precisely as described in the manufacturer’s protocol. PCR amplification products obtained were cloned directly into mammalian expression vector pCMV-Script (Stratagene, La Jolla, CA). Additional DESC1 5’ and 3’ sequence not present in CMV-Script clone, was obtained by 5’ and 3’ RACE analysis utilizing both 5’ and 3’ RACE systems (Gibco BRL, Gaithersburg, MD). A full-length DESC1 cDNA clone (pDESC1) was constructed following contig analysis of sequence obtained from pCMV-Script, 5’ and 3’ RACE clones. pDESC1 was generated by cloning of the DESC1 RT-PCR amplification product derived from normal human skin RNA (Invitrogen, Carlsbad, CA) into TOPO TA cloning vector pLND TOPO TA. This vector was transiently transfected into
modified 293 cells (EcR-293) containing a heterodimeric edcsyone and retinoid X receptor. Induction of DESC1, linked to a paramyxovirus V5 epitope tag, was accomplished by addition of Ponasterone A to the cell medium as described in the manufacturer’s protocol (Invitrogen, Carlsbad, CA). 72 hours post transfection, cell lysates were prepared, 20 µl lysate run on a 10% NuPAGE gel, and blotted using an XCell II Blot Module (Invitrogen, Carlsbad, CA). Presence of the recombiant DESC1 polypeptide was confirmed by WesternBreeze (Invitrogen, Carlsbad, CA) chemiluminescence detection, utilizing an antibody to the V5 epitope.

RT-PCR amplification

1.0 µg of total RNA was used for first strand cDNA synthesis in a total volume of 25 µl and reactions otherwise performed according to manufacter’s instructions (ProSTAR, Stratagene, La Jolla, CA). PCR amplification was performed in the presence of 2 units Taq 2000 DNA polymerase (Stratagene, La Jolla, CA), with reaction conditions: 10 mM Tris-HCl (pH 8.8), 50 mM KCl, 1.5 mM MgCl₂, 0.001% gelatin, 1 µM each primer, 200 µM dNTPs, and where appropriate, 0.25 µl [α-32P]dCTP (3000 Ci mmol⁻¹) in a final volume of 25 µl. Separate reactions were performed for each primer pair with reaction conditions; 96˚C 3 min followed by 94˚C 30 s, 55˚C 30 s, 72˚C 1 min for 31 cycles (HPRT) or 33 cycles (DESC1) and a final 5 min extension at 72˚C. PCR amplification of full-length DESC1 was performed utilizing the above cycling conditions, with an additional 1 min extension time for each cycle, and using the Advantage HF PCR kit (CLONTECH Laboratories Inc, Palo Alto, CA). PCR samples were then run through 2% agarose gels and presence of amplified product and correct product size verified by ethidium bromide fluorescence in the presence of 100 bp size markers (Gibco BRL, Gaithersburg, MD). Where appropriate, PCR products generated were electroblotted using a Bio-Rad Semi-Dri Electroblotter SD and transferred at 12 V/110 mA for 10 min. The membrane was removed, UV crosslinked and exposed to BioMax film (Eastman Kodak, Rochester, NY). Primers utilized in PCR reactions comprise: hypoxanthine phosphoribosyl transferase (HPRT) primers HPRT1, 5’-GTAATGACCAGTCAAGGGGAC-3’ and HPRT2, 5’-CAGCAAGCTTGACCCGTTCTAC-3’; DESC1 primers D3, 5’-TCACTGTCATATATGAGATATAAC-3’; D4, 5’-CACTGTCAGTGAAGGCTCATAT-3’; D10, 5’-CTGTCTCCAATCAAATGCGATAC-3’; D11, 5’-TGGACATGGAAACGTGTTTTATGAGATC-3’; D12, 5’-TGGCGTGGGATGAGACCTGGACCTTCA-3’; and D18, 5’-GAATGTTGACCTCGGGAGATG-3’. Location of primers on the DESC1 sequence is shown in Figure 1A. PCR amplification of the HPRT gene was performed as a control to demonstrate equal loading and to determine integrity of RNA. Primers were designed by computer analysis (Oligo 4.0; NBI, Hamel, MN) of available DNA sequence for each gene and, with the exception of primer set D11, D18, are intron-spanning precluding PCR amplification of any residual DNA present in RNA samples. Optimum cycle number for PCR amplification was pre-determined for each primer set using a mixture of RT reactions from 10 random normal and tumour samples (data not shown). This step is necessary to ensure that PCR amplification remains in the linear range and that production of PCR product does not plateau. Under reaction conditions used, quantity of PCR product is therefore directly proportional to the amount of radioactivity incorporated into the DNA.

Northern hybridization

Northern blot containing SCC RNA was generated by electrophoresis of 25 µg total RNA on a 1.5% glyoxal agarose gel according to manufacturer’s instructions (NorthernMax-Gly, Ambion, Austin Tx). Human Cancer Cell Line Multiple Tissue Northern Blot, Human Multiple Tissue Northern Blot and Human Multiple Tissue Northern Blot II were purchased from CLONTECH Laboratories Inc (Palo Alto, CA). Human Normal Tissue Blot III was obtained from Invitrogen (Carlsbad, CA). Blots were hybridized with [α-32P]dCTP-labelled DESC1 cDNA probe spanning 581 nucleotides of the DESC1 coding sequence (nucleotides 165–746) (Figure 1A), or control β-actin cDNA (CLONTECH Laboratories Inc, Palo Alto, CA) using ExpressHyb solution (CLONTECH Laboratories Inc, Palo Alto, CA), according to manufacturer’s protocol. Blots were then washed in 0.5 × SSC, 0.1% SDS for 30 min at RT, followed by 0.1 × SSC, 0.1% SDS for 1 h at 50˚C with 2 changes of solution and exposed to BioMax film.

DNA sequencing

DNA sequence of DESC1 was determined by cycle sequencing using a Thermo Sequenase system (Amersham, Cleveland, OH), followed by electrophoresis using the CastAway sequencing system (Stratagene, La Jolla, CA) according to manufacturer’s instructions.

Chromosomal localization of DESC1

Chromosomal mapping of DESC1 was performed by use of a Somatic Cell Hybrid Panel (Onkor, Gaithersburg, MD), with hybridization conditions for DESC1 probe as described above. Chromosomal mapping of DESC1 was additionally performed using the Genebridge 4 Radiation Hybrid Panel (Research Genetics Inc, Huntsville, AL) by PCR amplification using primers D11 and D18. The chromosomal location of DESC1 was then determined by accessing the Whitehead Institute/MIT Center for Genome Research radiation hybrid map of the human genome.

RESULTS

Isolation of DESC1 by representational difference analysis

Specimens for analysis comprising primary carcinoma, metastatic node and matched normal tissue were obtained from an individual who presented with a primary SCC of the tongue which was metastatic to regional neck nodes. Representational Difference Analysis (RDA) was performed on mRNA isolated from the normal oral tissue (buccal mucosa) and from an SCC-positive metastatic neck node. SCC-positive nodal tissue was chosen in preference to primary carcinoma, precluding the possibility of contamination of the carcinoma sample with normal oral epithelium. RDA was performed with carcinoDNA RNA as driver in the reaction, allowing selection of genes expressed in normal tissue but not in tumour tissue. 0.5% of the RDA final reaction was subject to PCR amplification and PCR products cloned into mammalian expression vector pCMV-Script.
Sequence analysis and characterization of DESC1

All recombinant clones were screened for inserts by PCR analysis and positive clones subject to sequence analysis using vector-specific T3 primers. BLASTN sequence analysis was then performed, using the public domain GenBank sequence database. One recombinant clone C35, carrying a 581 bp insert, was shown to represent a novel sequence, and possesses an open reading frame spanning the full length of the clone. The putative gene represented by this clone was designated Differentially Expressed in Squamous Cell Carcinoma Gene 1 (DESC1). C35 was devoid of consensus polyadenylation signals. In order to obtain the 3' end of the gene, 3' RACE analysis was performed on the remaining normal tissue mRNA used previously for RDA analysis. Sequence analysis of 3' RACE products allowed identification of two consensus polyadenylation signal sequences separated by 633 bp (Fig. 1A) and located at nucleotide positions 802 – 808 and 1441 – 1446. In order to obtain additional 5' sequence, 5' RACE was also performed. A full-length cDNA clone (pDESC1) was then generated by cloning of the DESC1 RT-PCR amplification product derived from normal human skin RNA. The resulting full-length DESC1 cDNA sequence is 1471 nucleotides in length (Genbank accession #AF064819) and is represented in Figure 1A. The DESC1 sequence was used to query the GenBank database. This analysis demonstrates strong sequence homology between DESC1 and a recently described serine protease, Human Airway Trypsin-like Protease (HAT) (Figure 1B). Sequence identity between the two genes at the amino acid level is 38% overall, and 51% when the serine protease catalytic domain only is compared (DESC1 residues 191–422). This information suggests that DESC1 is a novel member of the serine-protease gene family.

DESC1 contains a predicted open reading frame (ORF) comprising a minimum of 422 amino acids (Figure 1B) with putative initiation codon at nucleotide position 56 (based on sequence comparison with HAT) and termination codon at nucleotide position 1322. However, it is possible that the ORF may potentially extend 5' of nucleotide 56, since nucleotides 53–55 also encode a methionine residue and since no in-frame termination codons have been identified upstream of the putative initiation codon in the gene sequence so-far obtained. That DESC1 is indeed capable of encoding a polypeptide is demonstrated in Figure 2. The DESC1 gene was linked to an inducible expression vector (pIND TOPO TA), and expression induced in a modified 293 cell line (EcR-293) containing a heterodimeric ecdysone and retinoid X receptor. In this system, induction of DESC1 confirmed the presence of a 52 kDa polypeptide comprising DESC1 (47 kDa) and the V5 epitope tag (5 kDa).

The DESC1 polypeptide possesses four regions of conserved homology with members of the serine protease gene family which further suggest that DESC1 is a serine protease. These regions comprise the 3 domains surrounding the conserved amino acids of the catalytic triad known to be essential for function of the serine proteases (Cheah et al, 1990), histidine (residue 231), aspartic acid (residue 276) and serine (residue 372). The fourth domain comprises the catalytic cleavage site, cleaving between residues 190 (arginine) and 191 (isoleucine) (Figure 1B). In addition, DESC1 contains a hydrophobic region spanning residues 18–37 which represents a putative transmembrane domain. Thus DESC1 may, similar to HAT, be a transmembrane-spanning serine protease possessing an extracellular COOH-terminal catalytic region.

Expression studies of DESC1

Figure 3 demonstrates that DESC1 is expressed at a high level in the original normal tissue sample used for RDA analysis, but, in contrast, is expressed at a very low level in the primary tongue carcinoma and is absent from the metastatic nodal tissue derived from the same individual. Residual expression of DESC1 in the primary carcinoma may however result from low-level contamination of the tumour tissue with a small amount of surrounding normal cells.
Since DESC1 was isolated from normal buccal mucosa tissue and not from normal tongue (site of primary carcinoma), it was especially important to further determine whether DESC1 is differentially expressed consistently between normal tissue and carcinoma in patient specimens, other than the parental tissue used for RDA analysis. Figure 4 shows RT-PCR analysis of expression of DESC1 in 10 SCC specimens, and matched normal tissue, selected from diverse sites in the head and neck region. The results show lower levels of expression of DESC1 in 9/10 primary carcinomas relative to the level of expression in matched normal tissue. All normal tissue specimens were harvested from clinically appearing normal tissue located at least 3 cm from the tumour margin. Pathological evaluation of the normal tissue was performed. The relative levels of expression of DESC1 in normal tissue samples also varies between specimens, while the expression level of control gene HPRT remains constant.

Since DESC1 was isolated from normal oral mucosal tissue, which additionally contains cells of non-epithelial origin, it was essential to determine whether DESC1 expression was epithelial-specific. The expression level of DESC1 was therefore determined in epithelial cell lines and tissue. Figure 5 demonstrates that DESC1 is expressed in normal neonatal (NHEKNeo) and adult (NHEKAd) keratinocytes, and in normal prostate (PrEC) epithelial cells, confirming epithelial-specific expression of the gene. Figure 5 also demonstrates DESC1 expression in human skin and additionally in prostate tissue, supporting the detection of DESC1 in the epithelial cell lines. Expression of DESC1 is also seen in testes tissue but at a lower level. In contrast, no expression of DESC1 was detectable in COLO320 (colon carcinoma), MCF7 (breast carcinoma), A431 (epidermoid carcinoma), nor in cell lines of haematopoietic origin, K562 and U937. To date, expression of DESC1 has not been detected in any cell line of non-epithelial origin.

To further characterize the tissue-specific expression pattern of DESC1, Northern analysis was performed on a squamous cell carcinoma specimen, matched normal oral tissue, and other diverse human tissue samples and cell lines. The results are shown in Figure 6 and demonstrate a high degree of tissue specificity of DESC1 expression. Northern analysis, utilizing total RNA, shows expression of DESC1 in normal oral, gingival tissue but not in gingival squamous cell carcinoma from the same patient (Figure 6A). Figure 6A also shows faint, but detectable DESC1 expression in squamous cell carcinoma cell line SCC4, derived from a tongue carcinoma, but no expression in SCC25. DESC1 is also detectable in normal tonsil tissue (Figure 6B) using a total RNA blot. Under these conditions no significant level of DESC1 expression can be detected in any other tissue examined including prostate and testes. Figure 6C demonstrates, however, that when Northern analysis is performed with a higher degree of sensitivity, utilizing polyadenylated RNA rather than total RNA, DESC1 expression can again clearly be detected in prostate and testes. All other human tissues shown, and additionally heart, brain, placenta, lung, liver, skeletal muscle and kidney (Human Multiple Tissue Northern Blot, CLONTECH Laboratories Inc, Palo Alto, CA) (not shown) do not demonstrate detectable levels of expression of DESC1 suggesting that this gene is strongly tissue-specific in its pattern of expression. In addition, expression of DESC1 can be detected at a very low level in pancreas (data not shown). A panel of human cancer cell lines (Human Cancer Cell Line Multiple...
Tissue Northern Blot, CLONTECH Laboratories Inc, Palo Alto, CA), including haematopoietic cells HL-60, K-562, MOLT-4 and RAJI, colon carcinoma SW480, lung carcinoma A549, melanoma G361 and HeLa cells also lack detectable expression of \textit{DESC1} (data not shown). The results show one predominant transcript of 2.2 kb in normal matched tissue from SCC specimen #252 (Figure 6A), and two other transcripts of 1.6 and 0.6 kb in size, expressed at a lower level. The 6.0 kb transcript found in prostate mRNA was not detectable in normal oral tissue specimen #252 (Figure 6A) nor in RNA isolated from normal tonsil tissue (Figure 6B). However, the analyses were performed on total RNA only. Whether the 6.0 kb transcript is co-expressed with the other \textit{DESC1}-specific transcripts in oral epithelium, or is specific to prostate tissue, awaits Northern analysis of purified, polyadenylated RNA isolated from oral epithelial tissue. \textit{DESC1} expression in normal tonsil demonstrates only the 2.2 and 1.6 kb transcripts, which, in contrast, are expressed at equal intensities. \textit{DESC1} expression in the prostate shows expression of the 2.2 and 1.6 kb transcripts and an additional transcript of 6.0 kb, but again no detectable expression of the 0.6 kb transcript. The 1.6 kb transcript alone is detectable in testes and this may account for the lower level of \textit{DESC1} expression detected in the testes by RT-PCR analysis (Figure 5).

\textbf{DISCUSSION}

In this report we describe characterization of \textit{DESC1}, a novel human gene encoding a serine protease homologue. \textit{DESC1} expression has been detected in all normal specimens of head and neck-derived epithelium so far examined. In contrast, expression is reduced or absent in matched specimens of squamous cell carcinoma obtained from the same group of patients. The expression level of \textit{DESC1} in normal tissue samples varies between specimens, even when the tissue samples are taken from the same anatomical site, for example, pharyngeal specimens #54, #69, and

\begin{figure}[h]
\centering
\includegraphics[width=\textwidth]{figure6}
\caption{Expression of \textit{DESC1} in multiple human tissues and cell lines. Northern analysis using total RNA isolated from: (A) SCCHN-derived cell lines (SCC4 and SCC25), a gingival carcinoma (GIN#252(T)) and matched normal tissue (GIN#252(N)). Molecular weight markers used: Millennium Markers (Ambion, Austin, TX). (B) Normal human tissues (Human Normal Tissue Blot III) and (C) Polyadenylated RNA isolated from normal human tissues (Human Multiple Tissue Northern Blot II).}
\end{figure}

\begin{figure}[h]
\centering
\includegraphics[width=\textwidth]{figure7}
\caption{Chromosomal localization of \textit{DESC1}. Southern blot demonstrating hybridization of \textit{DESC1} cDNA (nucleotides 165–746) to a Somatic Cell Hybrid Panel. Human chromosome (1–22, X and Y) present in each hybrid is shown. Lanes 1 and 2 show total human DNA as positive control. Lanes 3 and 4 comprise total DNA from parental rodent cells used to produce hybrids.}
\end{figure}
To further investigate this observation, the level of expression of DESC1 in normal oral tissue samples from healthy individuals with no evidence of cancer should be determined. Such analysis will establish whether the observed variation in expression of DESC1 in normal epithelial tissue from cancer patients is representative of premalignant or hyperproliferative changes in clinically appearing normal epithelium, or simply the result of normal variation. The lower, but observable expression of DESC1 shown in some primary SCC specimens may represent lower overall expression in carcinoma tissue or, alternatively, may represent lack of tumour-specific expression and a degree of contamination of tumour specimens with normal tissue. In support of the former, a low level of expression of DESC1 can be detected in cell line SCC4, derived from a tongue carcinoma (Figure 4A). Thus, it is possible that DESC1 expression may be present in a reduced amount in many of the SCCHN tumours. It is also possible that variations in DESC1 expression may, in part, result from differences in the degree of tumour differentiation. Our preliminary observations suggest that expression of DESC1 does increase during enforced differentiation of normal epithelial cells (data not shown).

Northern analysis has allowed identification of 4 DESC1 transcripts, 6.0, 2.2, 1.6 and 0.6 kb in length. The additional identification of an internal consensus polyadenylation signal (nucleotides 802–807) suggests that the transcriptional organization of this locus is complex. The RT-PCR analysis of DESC1 expression shown in Figure 5 utilizes primers D10 and D11, specific to the 3′ end of DESC1. This region of the gene is downstream from, and therefore does not encompass, the internal consensus polyadenylation site, although it does contain part of the conserved catalytic domain of the gene (Figures 1A and 1B). Since this analysis allows detection of DESC1 expression in testes, and since, by Northern analysis, testes exhibit only the smaller 1.6 kb transcript, the data is consistent with identification of the 1.6 kb RNA as the transcript which encodes the DESC1 polypeptide comprising the serine protease. A second 3′ RACE product isolated demonstrates processing of a DESC1 RNA at the internal polyadenylation site (data not shown). This transcript terminates at nucleotide 823 and demonstrates that the internal polyadenylation site is functional. This alternative DESC1 transcript has not yet been further investigated, and it is unknown which transcript it may represent. The transcript cannot encode the putative DESC1 serine protease and is unlikely to encode an alternative reading frame, due to the presence of multiple upstream termination codons in the sequence so far obtained. However, should this alternative transcript comprise the 2.2 or 6.0 kb RNA, the remaining 5′ sequence of this RNA, yet to be determined, may be sufficient in length to encode another polypeptide. Expression of the 1.6 and 2.2 kb DESC1 transcripts appear equi-molar in normal tonsil tissue (Figure 6B), yet the 2.2 kb transcript predominates in the matched normal tissue sample from SCC#252 (Figure 6A). The reason for this difference is not evident, but further suggests that detailed mapping of the alternative DESC1 transcripts should be pursued.

The role of proteases, including serine proteases, in cancer development is well documented, and demonstrates an association between cancer development and activation of proteases (Liotta and Stetler-Stevenson, 1991). Less well described, is the inactivation of proteases associated with cancer development. However, it is interesting that a second, epithelial-specific serine protease, NES1, has been shown to be down-regulated during breast cancer development and it has been suggested that this gene may possess the functional properties of a tumour suppressor gene (Goyal et al, 1998). The results of our study suggest that DESC1 may similarly be down-regulated during the development of SCCHN, although we have no direct evidence to suggest that DESC1 also possesses the ability to function as a tumour suppressor. DESC1 is highly expressed in primary, normal human keratinocytes, epithelial cells previously shown to be capable of malignant conversion (Rhim et al, 1985). Functional studies are therefore underway in our laboratory to determine whether expression of DESC1 is altered during immortalization and transformation of normal human keratinocytes and whether enforced expression of DESC1 affects the growth characteristics of cells already transformed. Although the precise role of DESC1 in the development of SCCHN is unknown, the observation of altered DESC1 expression in the majority of tumours suggests that this gene may represent a useful marker for squamous cell carcinoma of the head and neck.

ACKNOWLEDGEMENTS

This work was supported by grants from the National Institutes of Health, CA63134 (National Cancer Institute) (JCL) and P01 DE12704 (National Institute for Dental and Craniofacial Research) (JCL and DES) and by grant 2P30CA16058 from the National Cancer Institute.

REFERENCES

Bockuhl U, Wolf G, Schmidt S, Schwendel A, Jahnke V, Dietel M and Peterson I (1998) Genomic alterations associated with malignancy in head and neck cancer. Head Neck 20: 145–151
Califano J, Van Der Riet P, Westra W, Nawroz H, Clayman G, Piantadosi S, Corio R, Lee D, Greenberg B, Koch W and Sidransky D (1996) Genetic progression model for head and neck cancer: implications for field cancerization. Cancer Res 56: 2488–2492
Cheah K-C, Leong L-E-C and Porter AG (1990) Site directed mutagenesis suggests close functional relationship between a human rhinovirus 3C cysteine protease and cellular trypsin-like serine proteases. J Biol Chem 265: 7180–7187
Dietchenko L, Lau YFC, Campbell AP, Chenchik A, Moqadam F, Huang B, Lukyanov S, Lukyanov K, Gurskaya N, Sverdlov ED and Siebert PD (1996) Suppression subtractive hybridization: A method for generating differentially regulated or tissue-specific cDNA probes and libraries. Proc Natl Acad Sci USA 93: 6025–6030
Field JK, Spandidos DA, Stell PM, Vaughan ED, Evan GI and Moore JP (1989) Elevated expression of the c-myc oncprotein correlates with poor prognosis in head and neck squamous cell carcinoma. Oncogene 4: 1463–1468
Goyal J, Smith KM, Cowan JM, Wazer DE, Lee SW and Band V (1998) The role for NES1 serine protease as a novel tumor suppressor. Cancer Res 58: 4782–4786
Grama AW, Lucas JM, Mountain RE, Schuller DE and Lang JC (1995) Efficient method for preparing normal and tumor tissue for RNA extraction. Biotechniques. 18: 228
Ke LD, Adler-Storthz K, Clayman GL, Yung AW, Chen Z (1998) Differential expression of epidermal growth factor receptor in human head and neck cancers. Head Neck 20: 320–327
Lang JC, Tobin EJ, Knobloch TJ, Bartynski KJ, Mountain RE, Nicholson R, De Young BR, Weghorst CM and Schuller DE (1998) Frequent mutation of p16 in squamous cell carcinoma of the head and neck. Laryngoscope 108: 923–928
Liotta LA and Stetler-Stevenson WG (1991) Tumor invasion and metastasis: An imbalance of positive and negative regulation. Cancer Res 51: 5054–5059
Loughran O, Clark Lj, Bond J, Baker A, Berry JJ, Edington KG, Ly IS, Simmons R, Haw R, Black DM, Newbold RF and Parkinson EK (1997) Evidence for the
inactivation of multiple replicative lifespan genes in immortal human squamous cell carcinoma keratinocytes. *Oncogene* **14**: 1955–1964

Michalides R, Van Veelen N, Hart A, Loftus B, Wientjens E and Balm A (1995) Overexpression of cyclin D1 correlates with recurrence in a group of forty-seven operable squamous cell carcinomas of the head and neck. *Cancer Res* **55**: 975–978

Nawroz H, van der Riet P, Hruban RH, Koch W, Ruppert JM and Sidransky D (1994) Allelotype of head and neck squamous cell carcinoma. *Cancer Res* **54**: 1152–1155

Reed AL, Califano J, Cairns P, Westra WH, Jones RM, Koch W, Ahrendt S, Eby Y, Sewell D, Nawroz H, Bartek J and Sidransky D (1996) High frequency of p16 (CDKN2/MTS-1/INK4A) inactivation in head and neck squamous cell carcinoma. *Cancer Res* **56**: 3630–3633

Somers KD, Merrick MA, Lopez ME, Incognito LS, Schechter GL and Casey G (1992) Frequent p53 mutations in head and neck cancer. *Cancer Res* **52**: 5997–6000

Xia W, Lau YK, Zhang HZ, Liu AR, Li L, Kiyokawa N, Clayman GL, Katz RL and Hung MC (1997) Strong correlation between c-erbB-2 overexpression and overall survival of patients with oral squamous cell carcinoma. *Clin Can Res* **3**: 5–9

Yamaoka K, Masuda K, Ogawa H, Takagi K, Umemoto N and Yasuoka S (1998) Cloning and characterization of the cDNA for human airway trypsin-like protease *J Biol Chem* **273**: 11895–11901